Sir,

Dengue is an increasingly prevalent tropical arbovirus infection with significant morbidity and mortality.\[[@ref1]\] The clinical presentation of dengue is the acute febrile illness with the classical triad of laboratory findings, hemoconcentration, atypical lymphocytosis and thrombocytopenia.\[[@ref1]\] In severe cases, the most serious form of dengue, dengue shock syndrome is seen and can result in death. Treatment of dengue is mainly based on the fluid replacement therapy.\[[@ref1]\] For prevention, the mosquito control is the key. The search for dengue vaccine is underway.\[[@ref2]\]

Of the several new drugs being researched for dengue treatment, the natural product research is a widely studied field.\[[@ref1]\] Indeed, there are many reports on natural products that have potential for treatment of dengue. However, only a few natural products are further evaluated in clinical pharmacology studies. The study on the potential use of *neem* (*Azadirachta indica Juss*) leaves for destroying dengue virus was published by Parida *et al*.\[[@ref3]\] In this report, in vitro study showed that aqueous extract of *neem* could inhibit dengue virus; however the in vivo study in mice model revealed no inhibitory activity.\[[@ref3]\] Another interesting report is published by Reis *et al*. In this report, immunomodulating and antiviral activities of *Uncaria tomentosa* on human monocytes infected with Dengue was presented.\[[@ref4]\] In this work, alkaloidal fraction in *Uncaria tomentosa* was effective in reducing monocyte infection rates and cytokine levels.\[[@ref4]\]

There are also some interesting publications on novel anti-dengue therapeutic agents. In the study by Lee *et al*, antiviral effects of three novel anti-dengue therapeutic agents, sulfated polysaccharides, suramin, pentosan polysulfate (PPS) and PI-88, were tested and it was shown that PI-88 was the only effect novel agent.\[[@ref5]\] Indeed, there are also other reports on other novel agents. For example, Prestwood *et al*. reported on the efficacy of c-Src protein kinase inhibitors in blocking assembly and maturation of dengue virus.\[[@ref6]\] Shigeta *et al*. also reported the good effectiveness of polyoxometalates in viral inhibition in mice model.\[[@ref7]\] On the other hand, Tassniyom *et al*. reported the unsuccessful usage of carbazochrome sodium sulfonate or AC-17 to prevent vascular permeability or shock caused by dengue virus.\[[@ref8]\] Focusing on the modern RNA technology, the use of mismatched double-stranded RNA was also trailed and reported for its good effectiveness as novel alternative anti-dengue therapeutic agent.\[[@ref9]\]

There are many dengue vaccines which are presently on trials. Vaughn *et al*. firstly reported on testing of a dengue two live-attenuated vaccine, strain 16681 PDK 53. in volunteers and presented for high immunogenicitiy but some minor adverse effects such as fever, headache and myalgia.\[[@ref10]\] Kanesa- thasan *et al*. reported another study of attenuated dengue virus vaccines developed by Aventis Pasteur that this vaccine alternative was safe and demonstrated immunogenicity.\[[@ref11]\]

Many similar studies using animal models, a useful tool for research on dengue virus have been conducted.\[[@ref12]\] However, there is no large study that confirms and leads to paradigm shift in treatment and prevention of dengue. More systematic researches on this area is still warranted.
